✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
LEE011 is an investigational drug.
There have been 81 clinical trials for LEE011. The most recent clinical trial was a Phase 3 trial, which was initiated on March 23rd 2022.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are one hundred and seventy-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for LEE011
|Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors||Innovative Therapies For Children with Cancer Consortium||Phase 1/Phase 2|
|Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors||Novartis Pharmaceuticals||Phase 1/Phase 2|
|Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation||Novartis Pharmaceuticals||Phase 1/Phase 2|
Top disease conditions for LEE011
Top clinical trial sponsors for LEE011
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LEE011||See Plans and Pricing||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||See Plans and Pricing|
|LEE011||See Plans and Pricing||Ribociclib intermediate and preparation method therefor||SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN)||See Plans and Pricing|
|LEE011||See Plans and Pricing||Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer||Novartis AG (Basel, CH)||See Plans and Pricing|
|LEE011||See Plans and Pricing||Compounds and compositions as inhibitors of MEK||Novartis AG (Basel, CH)||See Plans and Pricing|
|LEE011||See Plans and Pricing||Androgen receptor mutation||Novartis AG (Basel, CH)||See Plans and Pricing|
|LEE011||See Plans and Pricing||Methods of treating cancer patients with farnesyltransferase inhibitors||Kura Oncology, Inc. (La Jolla, CA)||See Plans and Pricing|
|LEE011||See Plans and Pricing||Heterocyclic estrogen receptor modulators and uses thereof||Genentech, Inc. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|LEE011||Australia||AU2014348657||2033-11-13||See Plans and Pricing|
|LEE011||Australia||AU2017245411||2033-11-13||See Plans and Pricing|
|LEE011||Australia||AU2019246853||2033-11-13||See Plans and Pricing|
|LEE011||Brazil||BR112016010716||2033-11-13||See Plans and Pricing|
|LEE011||Canada||CA2929181||2033-11-13||See Plans and Pricing|
|LEE011||China||CN105899232||2033-11-13||See Plans and Pricing|
|LEE011||Eurasian Patent Organization||EA201690987||2033-11-13||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|